FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study

FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study

Submitted by admin on October 31, 2023 - 9:23pm
Source: 
Yahoo/Reuters
News Tags: 
Vertex Pharmaceuticals
CRISPR Therapeutics
FDA
gene therapy
exa-cel
Headline: 
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
snippet: 

A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals and CRISPR Therapeutics could assess potential safety risks of their sickle cell disease gene therapy after approval.

Do Not Allow Advertisers to Use My Personal information